Rougier P, Sahmoud T, Nitti D, Curran D, Doci R, De Waele B, Nakajima T, Rauschecker H, Labianca R, Pector JC, Marsoni S, Apolone G, Lasser P, Couvreur ML, Wils J

Adjuvant portal-vein infusion of fluorouracil and heparin in colorectal cancer: a randomised trial. European Organisation for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group, the Gruppo Interdisciplinare Valutazione Interventi in Oncologia, and the Japanese Foundation for Cancer Research.

Lancet 1998; 1677-81. doi: 10.1016/s0140-6736(97)08169-5

Leggi ora

Sessa C, Capri G, Gianni L, Peccatori F, Grasselli G, Bauer J, Zucchetti M, Viganò L, Gatti A, Minoia C, Liati P, Van den Bosch S, Bernareggi A, Camboni G, Marsoni S

Clinical and pharmacological phase I study with accelerated titration design of a daily times five schedule of BBR3464, a novel cationic triplatinum complex.

Ann Oncol 2000; 977-83. doi: 10.1023/a:1008302309734

Leggi ora

Marsoni S

Efficacy of adjuvant fluorouracil and leucovorin in stage B2 and C colon cancer. International Multicenter Pooled Analysis of Colon Cancer Trials Investigators.

Semin Oncol 2001; 14-9. doi: 10.1053/sonc.2001.19723

Leggi ora

Olmi P, Crispino S, Fallai C, Torri V, Rossi F, Bolner A, Amichetti M, Signor M, Taino R, Squadrelli M, Colombo A, Ardizzoia A, Ponticelli P, Franchin G, Minatel E, Gobitti C, Atzeni G, Gava A, Flann M, Marsoni S

Locoregionally advanced carcinoma of the oropharynx: conventional radiotherapy vs. accelerated hyperfractionated radiotherapy vs. concomitant radiotherapy and chemotherapy--a multicenter randomized trial.

Int J Radiat Oncol Biol Phys 2003; 78-92. doi: 10.1016/s0360-3016(02)03792-6

Leggi ora

Lacombe D, Butler-Smith A, Therasse P, Fumoleau P, Burtles S, Calvert H, Marsoni S, Sessa C, Verweij J

Cancer drug development in Europe: a selection of new agents under development at the European Drug Development Network.

Cancer Invest 2003; 137-47. doi: 10.1081/cnv-120016408

Leggi ora

Sessa C, Perotti A, Salvatorelli E, Minotti G, Viganò L, Lladò A, Capri G, Locatelli A, Colombini S, Peccatori F, Voi M, Marsoni S, Gianni L

Phase IB and pharmacological study of the novel taxane BMS-184476 in combination with doxorubicin.

Eur J Cancer 2004; 563-70. doi: 10.1016/j.ejca.2003.11.023

Leggi ora

Labianca R, Fossati R, Zaniboni A, Torri V, Marsoni S, Nitti D, Boffi L, Scatizzi M, Tardio B, Mastrodonato N, Banducci S, Consani G, Pancera G

Randomized trial of intraportal and/or systemic adjuvant chemotherapy in patients with colon carcinoma.

J Natl Cancer Inst 2004; 750-8. doi: 10.1093/jnci/djh132

Leggi ora

Marsoni S, Damia G

Molecular targeting: new therapeutic strategies to improve tumour apoptosis.

Ann Oncol 2004; iv229-31. doi: 10.1093/annonc/mdh931

Leggi ora

Sessa C, De Braud F, Perotti A, Bauer J, Curigliano G, Noberasco C, Zanaboni F, Gianni L, Marsoni S, Jimeno J, D'Incalci M, Dall'ó E, Colombo N

Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails.

J Clin Oncol 2005; 1867-74. doi: 10.1200/JCO.2005.09.032

Leggi ora

Sessa C, Marsoni S

Randomized single-agents trials in recurrent epithelial ovarian cancer.

Int J Gynecol Cancer 2005; 247-51. doi: 10.1111/j.1525-1438.2005.00437.x

Leggi ora

Sessa C, Viganò L, Grasselli G, Trigo J, Marimon I, Lladò A, Locatelli A, Ielmini N, Marsoni S, Gianni L

Phase I clinical and pharmacological evaluation of the multi-tyrosine kinase inhibitor SU006668 by chronic oral dosing.

Eur J Cancer 2006; 171-8. doi: 10.1016/j.ejca.2005.09.033

Leggi ora

Sessa C, Cresta S, Cerny T, Baselga J, Rota Caremoli E, Malossi A, Hess D, Trigo J, Zucchetti M, D'Incalci M, Zaniboni A, Capri G, Gatti B, Carminati P, Zanna C, Marsoni S, Gianni L

Concerted escalation of dose and dosing duration in a phase I study of the oral camptothecin gimatecan (ST1481) in patients with advanced solid tumors.

Ann Oncol 2007; 561-8. doi: 10.1093/annonc/mdl418

Leggi ora

Sessa C, Perotti A, Lladò A, Cresta S, Capri G, Voi M, Marsoni S, Corradino I, Gianni L

Phase I clinical study of the novel epothilone B analogue BMS-310705 given on a weekly schedule.

Ann Oncol 2007; 1548-53. doi: 10.1093/annonc/mdm198

Leggi ora

Marsoni S, Damia G, Camboni G

A work in progress: the clinical development of histone deacetylase inhibitors.

Epigenetics 2008; 164-71. doi: 10.4161/epi.3.3.6253

Leggi ora

Sessa C, Cresta S, Noberasco C, Capri G, Gallerani E, De Braud F, Zucchetti M, D'Incalci M, Locatelli A, Marsoni S, Corradino I, Minoia C, Zintl P, Gianni L

Phase I clinical and pharmacokinetic study of trabectedin and cisplatin in solid tumours.

Eur J Cancer 2009; 2116-22. doi: 10.1016/j.ejca.2009.04.002

Leggi ora

Frapolli R, Zucchetti M, Sessa C, Marsoni S, Viganò L, Locatelli A, Rulli E, Compagnoni A, Bello E, Pisano C, Carminati P, D'Incalci M

Clinical pharmacokinetics of the new oral camptothecin gimatecan: the inter-patient variability is related to alpha1-acid glycoprotein plasma levels.

Eur J Cancer 2010; 505-16. doi: 10.1016/j.ejca.2009.11.006

Leggi ora

Rojo F, Gracias E, Villena N, Cruz T, Corominas JM, Corradino I, Cedeño M, Campas C, Osorio M, Iznaga N, Bellosillo B, Rovira A, Marsoni S, Gascon P, Serrano S, Sessa C, Crombet T, Albanell J

Pharmacodynamic trial of nimotuzumab in unresectable squamous cell carcinoma of the head and neck: a SENDO Foundation study.

Clin Cancer Res 2010; 2474-82. doi: 10.1158/1078-0432.CCR-09-3042

Leggi ora

Mello-Grand M, Singh V, Ghimenti C, Scatolini M, Regolo L, Grosso E, Zambelli A, Da Prada GA, Villani L, Fregoni V, Baiardi P, Marsoni S, Miller WR, Costa A, Chiorino G

Gene expression profiling and prediction of response to hormonal neoadjuvant treatment with anastrozole in surgically resectable breast cancer.

Breast Cancer Res Treat 2010; 399-411. doi: 10.1007/s10549-010-0887-y

Leggi ora

Sargent DJ, Marsoni S, Monges G, Thibodeau SN, Labianca R, Hamilton SR, French AJ, Kabat B, Foster NR, Torri V, Ribic C, Grothey A, Moore M, Zaniboni A, Seitz JF, Sinicrope F, Gallinger S

Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer.

J Clin Oncol 2010; 3219-26. doi: 10.1200/JCO.2009.27.1825

Leggi ora

Floriani I, Garassino MC, Broggini M, Veronese S, Marsoni S, Marabese M, Farina G, Scanni A

Role of cetuximab in the treatment of patients with NSCLC: are we throwing out the baby with the bath water?

J Clin Oncol 2010; e467; author reply e468. doi: 10.1200/JCO.2010.28.5973

Leggi ora

Perotti A, Locatelli A, Sessa C, Hess D, Viganò L, Capri G, Maur M, Cerny T, Cresta S, Rojo F, Albanell J, Marsoni S, Corradino I, Berk L, Rivera VM, Haluska F, Gianni L

Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine.

J Clin Oncol 2010; 4554-61. doi: 10.1200/JCO.2009.27.5867

Leggi ora

Gallerani E, Bauer J, Hess D, Boehm S, Droege C, Jeckelmann S, Miani M, Herrmann R, Marsoni S, Sperka S, Sessa C

A phase I study of the oral platinum agent satraplatin in sequential combination with capecitabine in the treatment of patients with advanced solid malignancies.

Acta Oncol 2011; 1105-10. doi: 10.3109/0284186X.2010.543697

Leggi ora

Sinicrope FA, Foster NR, Thibodeau SN, Marsoni S, Monges G, Labianca R, Kim GP, Yothers G, Allegra C, Moore MJ, Gallinger S, Sargent DJ

DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy.

J Natl Cancer Inst 2011; 863-75. doi: 10.1093/jnci/djr153

Leggi ora

Garassino MC, Marsoni S, Floriani I

Testing epidermal growth factor receptor mutations in patients with non-small-cell lung cancer to choose chemotherapy: the other side of the coin.

J Clin Oncol 2011; 3835-7; author reply 3837-9. doi: 10.1200/JCO.2011.36.7847

Leggi ora

Damia G, Broggini M, Marsoni S, Venturini S, Generali D

New omics information for clinical trial utility in the primary setting.

J Natl Cancer Inst Monogr 2011; 128-33. doi: 10.1093/jncimonographs/lgr032

Leggi ora

Mandala M, Clerici M, Corradino I, Vitalini C, Colombini S, Torri V, De Pascale A, Marsoni S

Incidence, risk factors and clinical implications of venous thromboembolism in cancer patients treated within the context of phase I studies: the 'SENDO experience'.

Ann Oncol 2012; 1416-21. doi: 10.1093/annonc/mdr524

Leggi ora

Olmos D, A'hern RP, Marsoni S, Morales R, Gomez-Roca C, Verweij J, Voest EE, Schöffski P, Ang JE, Penel N, Schellens JH, Del Conte G, Brunetto AT, Evans TR, Wilson R, Gallerani E, Plummer R, Tabernero J, Soria JC, Kaye SB

Patient selection for oncology phase I trials: a multi-institutional study of prognostic factors.

J Clin Oncol 2012; 996-1004. doi: 10.1200/JCO.2010.34.5074

Leggi ora

Parma G, Mancari R, Del Conte G, Scambia G, Gadducci A, Hess D, Katsaros D, Sessa C, Rinaldi A, Bertoni F, Vitali A, Catapano CV, Marsoni S, van de Velde H, Colombo N

An open-label phase 2 study of twice-weekly bortezomib and intermittent pegylated liposomal doxorubicin in patients with ovarian cancer failing platinum-containing regimens.

Int J Gynecol Cancer 2012; 792-800. doi: 10.1097/IGC.0b013e318251051a

Leggi ora

Mandalà M, Grosso F, Vitalini C, Corradino I, Sanfilippo R, Colombini S, Clerici M, Labianca R, De Pascale A, Marsoni S

Venous thromboembolism is a relevant and underestimated adverse event in cancer patients treated in phase I studies.

Br J Cancer 2012; 612-6. doi: 10.1038/bjc.2012.325

Leggi ora

Inviaci un messaggio